%PDF-1.4
%
54 0 obj
<>
endobj
51 0 obj
<>
endobj
106 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T15:10:47Z
2024-03-28T14:52:44-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T14:52:44-07:00
application/pdf
Heather
2001-950.august
uuid:d49ca6bc-1dd1-11b2-0a00-fe08275d6100
uuid:d49ca6be-1dd1-11b2-0a00-aa0000000000
endstream
endobj
40 0 obj
<>
endobj
41 0 obj
<>
endobj
55 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
128 0 obj
[132 0 R]
endobj
129 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.13989 Tw 10 0 0 10 54 713.1616 Tm
(number of people who turned up for clinical examination)Tj
0.091 Tw 0 -1.2 TD
(compared with the number that completed the CCQ might)Tj
0.13901 Tw T*
[(be attributed to a number of factors. )17.8 (The interviews were)]TJ
0.12019 Tw T*
(conducted during the evenings, when people were usually)Tj
-0.0304 Tw T*
(available, whereas the clinical examinations were conducted)Tj
0.1393 Tw T*
(in the 2 hospitals in the mornings when people would be)Tj
0.03709 Tw T*
[(expected to be at work. )54.9 (A)-231.9 (better approach would have been)]TJ
0.3154 Tw T*
(to examine the respondents at home, but this was not)Tj
0.3624 Tw T*
(feasible because of the shortage of rheumatologists in)Tj
0.217 Tw T*
[(Kuwait. )54.9 (A)-411.8 (second factor for the low turnout for clinical)]TJ
0.0426 Tw T*
(examination might be that examination was performed in 2)Tj
-0.00011 Tc 0.1541 Tw T*
(hospitals that, in many cases, were far from respondents\222)Tj
0 Tc 0.0779 Tw T*
(homes. No doubt, the low response rate also has statistical)Tj
0.1826 Tw T*
(implications in the sense that those patients who did not)Tj
0.10339 Tw T*
[(report for clinical examinations might have dif)17.8 (ferent char-)]TJ
-0.00011 Tc -0.02499 Tw T*
[(acteristics from those who did. Naturally)64.8 (, statistical analyses)]TJ
0 Tc 0.20399 Tw T*
(will only reflect the measurements and characteristics of)Tj
0.23129 Tw T*
[(those patients who reported for clinical examination. )54.9 (As)]TJ
0.15221 Tw T*
[(well, the test\222)54.9 (s power for detecting statistical significance)]TJ
0.0609 Tw T*
[(will be af)17.8 (fected by the low response rate. )17.8 (Therefore during)]TJ
-0.0049 Tw T*
(the future expansion of this study we intend to conduct clin-)Tj
0.08051 Tw T*
(ical examinations in polyclinics, which are equally distrib-)Tj
0.01109 Tw T*
[(uted in all districts close to respondents\222)-187.2 (homes. )17.8 (The female)]TJ
0.15961 Tw T*
(preponderance in rheumatic diseases and their prevalence)Tj
0.0168 Tc 0.3582 Tw T*
(reported during the pilot study were consistent with)Tj
-0.00011 Tc 0.0697 Tw T*
(previous studies)Tj
0 Tc 0 Tw 6.5 0 0 6.5 119.4036 416.4616 Tm
[(8,1)56.7 (1,12)]TJ
0.0696 Tw 10 0 0 10 138.5348 413.1616 Tm
[(. )17.8 (The preliminary findings that female)]TJ
0.22701 Tw -8.4535 -1.2 Td
(sex, increasing age, marriage, and being a housewife or)Tj
0.1248 Tw T*
(retired were associated with high prevalence of rheumatic)Tj
0.02499 Tw T*
[(diseases need to be confirmed by the major study)64.9 (.)]TJ
-0.00011 Tc 0.00259 Tw 1.2 -1.2 Td
[(The )54.8 (Arabic version of the )17.7 (WHO-ILAR COPCORD CCQ)]TJ
0 Tc 0.09869 Tw -1.2 -1.2 Td
(would appear to be a reliable, culturally acceptable, sensi-)Tj
0.29289 Tw T*
(tive, specific, and easy instrument for the screening of)Tj
0.2879 Tw T*
[(rheumatic diseases in )54.9 (Arabic-speaking communities. )17.7 (W)79.8 (e)]TJ
-0.0269 Tw T*
(intend to use it to study the prevalence of rheumatic diseases)Tj
0.17461 Tw T*
[(among Kuwaitis and recommend its use in other )54.9 (Arabic-)]TJ
0.02499 Tw T*
(speaking countries.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(AKNOWLEDGMENT)Tj
/TT0 1 Tf
0.33299 Tw 8 0 0 8 54 259.1616 Tm
[(The authors thank Prof. John Darmawan, )17.7 (WHO-APLAR COPCORD)]TJ
0 Tc 0.3429 Tw 0 -1.25 TD
[(Coordinator \(WHO Collaborating Center)39.8 (, Community-based Epidemi-)]TJ
0.0369 Tw T*
[(ology)64.9 (, )17.8 (T)34.9 (reatment and Prevention of Rheumatic Disease, Seroja Rheumatic)]TJ
0.06619 Tw T*
[(Center)39.8 (, Semarang, Indonesia\) for providing the English version of )17.7 (WHO-)]TJ
-0.00011 Tc 0.02499 Tw T*
(ILAR COPCORD-CCQ.)Tj
/TT1 1 Tf
0 Tw 10 0 0 10 54 197.1616 Tm
(REFERENCES)Tj
/TT0 1 Tf
0.02499 Tw 8 0 0 8 61 187.1616 Tm
[(1.)-875.1 (Factors associated with prevalent self-reported arthritis and other)]TJ
1.675 -1.25 Td
[(rheumatic conditions [editorial]. MMWR Morb Mortal )17.7 (Wkly Rep)]TJ
0 Tc 0 Tw T*
(1996;45:487-91.)Tj
0.0249 Tw -1.675 -1.25 Td
[(2.)-875 (Badley EM, )17.7 (W)79.8 (ang PP)110.8 (. )54.8 (Arthritis and the aging population:)]TJ
1.675 -1.25 Td
(projections of arthritis prevalence in Canada 1991 to 2031. )Tj
T*
(J Rheumatol 1998;25:138-44.)Tj
-1.675 -1.25 Td
[(3.)-875 (Badley EM, Rasooly I, )17.8 (W)79.8 (ebster GK. Relative importance of)]TJ
1.675 -1.25 Td
(musculoskeletal diseases as a cause of chronic health problems,)Tj
T*
[(disability)65 (, and health care utilization: findings from the 1990)]TJ
T*
[(Ontario Health Survey)64.9 (. J Rheumatol 1994;21:505-14.)]TJ
31.325 77.171 Td
[(4.)-875 (Muirden KD. )17.7 (The developing relationship between the )17.7 (W)79.8 (orld)]TJ
1.675 -1.25 Td
[(Health Or)17.8 (ganization and International League )54.8 (Against Rheumatism.)]TJ
T*
(J Rheumatol 1991;18:793-5.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Dans LF)79.7 (, )17.7 (T)69.7 (ankeh-T)69.7 (orres S, )54.8 (Amanta CM, Penser)17.7 (ga EG. )17.7 (The)]TJ
0 Tc 1.675 -1.25 Td
[(prevalence of rheumatic disease in a Filipino urban population: )54.9 (A)]TJ
T*
[(WHO-ILAR COPCORD study)65 (. J Rheumatol 1997;24:1814-9.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Darmawan J, )17.7 (V)111 (alkenbur)17.7 (g HA, Muirden KD, )17.7 (W)39.7 (igley RD.)]TJ
0 Tc 1.675 -1.25 Td
(Epidemiology of rheumatic disease in rural and urban populations)Tj
T*
[(in Indonesia: )54.8 (A)-202 (W)79.8 (orld Health Or)17.8 (ganization International League)]TJ
-0.00011 Tc T*
[(Against Rheumatism COPCORD study)64.8 (, stage 1, phase 2. )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 1992;51:525-8.)Tj
-1.675 -1.25 Td
[(7.)-875 (Chou CT)74 (, Pei L, Chang DM, Lee CF)79.8 (, Schumacher HR, Liang NH.)]TJ
1.675 -1.25 Td
[(Prevalence of rheumatic disease in )17.8 (T)69.8 (aiwan: )54.9 (A)-219.8 (population study of)]TJ
T*
[(urban, suburban, rural dif)17.8 (ferences. J Rheumatol 1994;21:302-6.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Chaiamnuay P)110.8 (, Darmawan J, Muirden KD, )54.8 (Assawatanabodee P)110.7 (.)]TJ
0 Tc 1.675 -1.25 Td
[(Epidemiology of rheumatic disease in rural )17.8 (Thailand: a )17.8 (WHO-)]TJ
T*
[(ILAR COPCORD study)64.9 (. J Rheumatol 1998;25:1382-7.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Lee P)110.7 (, Helewa )54.8 (A, Smythe HA, Bombardier C, Goldsmith CH.)]TJ
0 Tc 1.675 -1.25 Td
(Epidemiology of musculoskeletal diseases and related disability in)Tj
T*
[(Canada. J Rheumatol 1985;12:1)36.9 (169-73.)]TJ
-2.175 -1.25 Td
[(10.)-875 (W)39.8 (igley R, Zhang NZ, Zeng QY)128.9 (, et al. Rheumatic diseases in China:)]TJ
2.175 -1.25 Td
(ILAR-China study comparing the prevalence of rheumatic)Tj
T*
(symptoms in northern and southern rural populations. J Rheumatol)Tj
0 Tw T*
(1994;21:1484-90.)Tj
0.0249 Tw -2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Farooqi )54.8 (A, Gibson )17.7 (T)74 (. Prevalence of major rheumatic diseases in the)]TJ
2.1381 -1.25 Td
(adult population of north Pakistan. Br J Rheumatol 1998;37:491-5.)Tj
-2.175 -1.25 Td
[(12.)-875 (Bennett K, Cardiel MH, Ferraz MB, Riedemann P)110.8 (,)0.1 ( Goldsmith CH,)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(T)34.8 (ugwell P)110.7 (. Community screening for rheumatic disorders: cross)]TJ
0 Tc T*
(cultural adaptation and screening characteristics of the COPCORD)Tj
T*
(Core Questionnaire in Brazil, Chile and Mexico. J Rheumatol)Tj
0 Tw T*
(1997;24:160-8.)Tj
0.0249 Tw -2.175 -1.25 Td
[(13.)-875 (Guillemin F)79.8 (, Bombardier C, Beaton D. Cross-cultural adaptation of)]TJ
2.175 -1.25 Td
(health-related quality of life measures: Literature review and)Tj
T*
(proposed guidelines. J Clin Epidemiol 1993;46:1417-32.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Fries J, Hochber)17.7 (g MC, Medsger )17.7 (T)79.7 (A, Hunder GG, Bombardier C,)]TJ
0 Tc 2.175 -1.25 Td
[(and the )54.9 (American College of Rheumatology Diagnostic and)]TJ
T*
(Therapeutic Criteria Committee. Criteria for rheumatic disease.)Tj
T*
(Arthritis Rheum 1994;37:545-62.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Altman RD. Criteria for classification of clinical osteoarthritis. )]TJ
0 Tc 2.175 -1.25 Td
(J Rheumatol 1991;18 Suppl 27:10-2.)Tj
-2.175 -1.25 Td
[(17.)-875 (W)79.8 (olfe F)79.8 (,)0.1 ( Smythe HA, )36.8 (Y)111.1 (unus MB, et al. )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology 1990 criteria for the classification of fibromalgia.)Tj
T*
[(Report of the Multicenter Criteria Committee. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1990;33:160-72.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (T)69.8 (an EM, Cohen )54.8 (AS, Fries JF)79.8 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (W)79.7 (allace SL, Robinson H, Masi )54.8 (A)111 (T)73.9 (, Decker JL, McCarty DJ, )36.8 (Y)111 (u)-0.1 ( )17.7 (TF)79.7 (.)]TJ
2.175 -1.25 Td
(Preliminary criteria for the classification of the acute arthritis of)Tj
0 Tc T*
[(primary gout. )54.9 (Arthritis Rheum 1977;20:895-900.)]TJ
-2.175 -1.25 Td
[(20.)-875 (Moll JMH, )17.7 (W)39.8 (right )17.7 (V)129.2 (.)0.1 ( New )36.8 (Y)100.1 (ork clinical criteria for ankylosing)]TJ
2.175 -1.25 Td
[(spondylitis: )54.9 (A)-219.8 (statistical evaluation. )54.9 (Ann Rheum Dis 1973;)]TJ
0 Tw T*
(32:354-63.)Tj
0.0249 Tw -2.175 -1.25 Td
[(21.)-875 (Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic)]TJ
2.175 -1.25 Td
(criteria for mixed connective tissue disease. Study of 593 patients. )Tj
T*
(J Rheumatol 1989;16:328-34.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Al-A)54.9 (wadhi, et al: )17.7 (Arabic scr)36.9 (eening questionnair)36.9 (e)]TJ
0 Tw 60.9375 -0.0313 Td
(1759)Tj
ET
0 0 0 0 scn
/GS0 gs
101.25 57.75 407.5 -10.83 re
f*
0.5 w
101.25 57.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
93 0 obj
<>
endobj
111 0 obj
<>
endobj
62 0 obj
<>
endobj
27 0 obj
<>
endobj
57 0 obj
<>
endobj
59 0 obj
<>
endobj
87 0 obj
<>stream
HVPTι"bzW6@gVeQ >v!j0:L1Qcx6vujb|6GGcJ3hսd{s?B h(Jzo߆ 欧tlQbjl UUgv-+@XZ1|skJ{G&\V/yЧ_G| 3+vM@
{mnCūGVgw_I{uyɩӿbJ65`+T|N&DPx-r0utt+Xh?wP8X[h@ U cP+8`=v'h/6"bT?#hgV?^"(2v& eu ''bcX.1j+aV3r=N3/'ڄ0xT/EW@$'r$za2ǚOȀ0]LdpNLJe>{Ed_b棒;lh=1IFZݭmVuэ>C0qb&2n38ઈ0+M8#[YQn]$23A=kuqYbL/R9WߪJb]!섓KC1#u{"Z_wqv"q&"L2}).H#
9\^TR\zEk):iD\ܫ%=ryv/3}qMbhm<$-8UʮJ,5bX&o^8J|9U.+>yJ_kQ Wk|TQ]Z6]jݎ~o'MӊR*kj`WU2IeWGc,G.OT@J1Yjnd=0}g;ŮUf#!Be;<(My"_LtQ*9ޭkbBq1ѝ:>!}dmÜMU@fT#6o)?%:Eژ/d?keO,=-ǖ"J4kfS7\2
t9Z!7,K7OUe/}s;
bԵ#_\ɶFldtJ_lfuq
iQd0a7ۧ"cCJO;XԈb?%TRX#ˌ}JʻU5LYU#[XWΘryA)3nõ$QbxmonÍlk01akO|⏚WL7\K]VB}'&,SgY;1n Kfσ\qKZ-m>6dwQWM@o0L$L),,3|/5Юe67[%`/f?>0?ZfJ
{M64$N2QمB./κ\vV5x0Y3>1xSL5ilM#cwӸ_h3,}TLGo@SuIHok$]a%